| |
FDA Grants Priority Review for New Kaletra Tablets
|
| |
| |
On May 3, 2005, Abbott announced that it submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for a new, tablet formulation of its protease inhibitor Kaletra (lopinavir/ritonavir). Abbott announced that the FDA has assigned priority review status to the NDA. As a result, a decision regarding approval of the new tablets is expected before year-end.
|
|
| |
| |
|
|
|
